

1 Untargeted metabolomic study of autism in newborn screening samples: a pilot study.

2
3 Julie Courraud^{1,2}, Madeleine Ernst^{1,2}, Susan Svane Laursen¹, Arieh S. Cohen¹

4
5 ¹ Section for Clinical Mass Spectrometry, Department of Congenital Disorders, Danish Center for
6 Neonatal Screening, Statens Serum Institut Copenhagen, Copenhagen, Denmark

7 ² iPSYCH, The Lundbeck Foundation Initiative for Integrative Psychiatric Research, Aarhus, Denmark

8
9 **Correspondence:** Julie Courraud (julc@ssi.dk), Section for Clinical Mass Spectrometry, Department
10 of Congenital Disorders, Danish Center for Neonatal Screening, Statens Serum Institut, Artillerivej 5,
11 2300 Copenhagen S, Denmark

12 ORCID 0000-0002-6797-7129

13 14 **Abstract:**

15 **Background**

16 The etiopathology of autism spectrum disorder (ASD) is unclear. Main risk factors include both genetic
17 and non-genetic factors, especially prenatal and perinatal events. The Danish Neonatal Screening
18 Biobank in connection with registry data provides unique opportunities to study early signs of disease.
19 Therefore, we aimed to study the metabolomic profiles of dried blood spot (DBS) of newborns later
20 diagnosed with ASD.

21 **Methods**

22 From the iPsych cohort, we randomly selected 37 subjects born in 2005 and diagnosed with ASD in
23 2012 (cases) together with 37 matched controls and submitted their biobanked DBS to an LC-MS/MS-
24 based untargeted metabolomics protocol. Raw data were preprocessed using MZmine 2.41.2 and

25 metabolites were subsequently putatively annotated using mzCloud, GNPS feature-based molecular
26 networking and other metabolome mining tools (MolNetEnhancer). Statistical analyses and data
27 visualization included principal coordinates analyses, PERMANOVAs, t-tests, and fold-change
28 analyses.

29 **Results**

30 4360 mass spectral features were detected, of which 150 could be putatively annotated at a high
31 confidence level. Chemical structure information at a broad level could be retrieved for a total of 1009
32 metabolites, covering 31 chemical classes including bile acids, various lipids, nucleotides, amino acids,
33 acylcarnitines and steroids. Although the untargeted analysis revealed no clear distinction between
34 cases and controls, 18 compounds repeatedly reported in the ASD literature could be detected in our
35 study and three mass spectral features were found differentially abundant in cases and controls before
36 FDR correction. In addition, our results pinpointed important other factors influencing chemical
37 profiles of newborn DBS samples such as gestational age, age at sampling and month of birth.

38 **Limitations**

39 Inherent to pilot studies, our sample size was insufficient to reveal metabolic markers of ASD.
40 Nevertheless, we were able to establish an efficient metabolomic data acquisition and analysis pipeline
41 and flag main confounders to be considered in future studies.

42 **Conclusions**

43 In this first untargeted DBS metabolomic study, newborns later diagnosed with ASD did not show a
44 significantly different metabolic profile when compared to controls. Nevertheless, our method covered
45 many metabolites associated with ASD in previous studies, suggesting that biochemical markers of
46 ASD are present at birth and may be monitored during newborn screening.

47

48 **Keywords:** autism, dried blood spots, untargeted metabolomics, newborn screening, biomarkers

49

50 **Background**

51 The etiopathology of ASD is still unclear and today ASD is diagnosed based on behavioral signs and
52 assessment of communication skills [1,2]. How the condition should be classified is debated [3,4], as
53 well as which tests offer the most reliable conclusions [1]. In Europe, detection services based on
54 behavioral signs are usually accessed on average at 18 months of age, and diagnosis occurs on average
55 at 36 months of age [5]. In this setting, early intervention is a challenge and has been reported to start in
56 Europe at 42 months of age on average [5]. Whether behavioral impairments are reflected in the blood
57 as biochemical abnormalities is still unsure, but the quest for biomarkers is legitimate, as they would
58 represent a useful tool to help in the diagnosis and treatment of ASD and in understanding its
59 underlying molecular mechanisms [6].

60

61 The main risk factors for ASD include genetic [7,8] and non-genetic factors, especially exposure during
62 fetal life [1,9–11]. Prenatal stress could influence fetal brain development and interact with genetic
63 predispositions thereby enhancing the risk of future psychiatric disorders [12,13]. Among prenatal
64 outcomes, maternal infection accompanied by fever during the second trimester of pregnancy has been
65 found to increase the risk of ASD twofold approximately [14]. Among perinatal outcomes, preterm
66 birth (<37 weeks) and low birthweight (small for gestational age) have been associated with an
67 increased risk of ASD as well as high frequency ventilation and intracranial hemorrhage [15]. Low
68 Apgar scores, a score used to summarizing vital signs and assess health in newborns [16], also have
69 recently been associated with an increased risk of developing ASD [17].

70

71 Gastrointestinal tract disorders are often reported in ASD children, along with certain foods or diets
72 impacting the severity of symptoms [18–21]. There is a growing evidence of strong interactions

73 between gut and brain through microbiota [22,23], and these observations support the notion that ASD
74 is associated with metabolic malfunction such as decrease in sulphation capacity [18], and potentially
75 connected to gut microbial populations and functions [20]. It has also been shown that many small
76 molecules differing between normally-developing and ASD individuals likely result from microbial
77 metabolism [20,24,25]. Recently, plasma and stool metabolites have been associated with poor
78 communication scoring at age 3, and with good prediction of autism by age 8 [26]. Sharon and
79 collaborators (Sharon et al. 2019) have shown that microbiome and metabolome profiles of mice
80 harboring human microbiota predict that specific bacterial taxa and their metabolites modulate ASD
81 behaviors. They found that taurine and 5-amiovaleric acid (5AV) had significantly lower levels in ASD
82 mice and could show that when feeding BTBR mice either taurine or 5AV, autism-like symptoms such
83 as repetitive behavior and decreased social interaction could be decreased. In an intervention study,
84 treatment with *Lactobacillus reuteri* has been shown to have beneficial effects on ASD-related social
85 disturbances in mice [27]. In humans, intestinal microbiota transplantation has shown very promising
86 results, both against gastrointestinal tract symptoms and ASD symptoms, granting the therapy a ‘fast-
87 track’ status by the FDA [28]. Among the plasma metabolites showing average to good classification
88 capacity between the treated children and the controls, sarcosine, tyramine O-sulfate and inosine 5’-
89 monophosphate were selected as most discriminant [29]. Many of these studies postulate that
90 microbiota-derived molecules are transported across the blood-brain-barrier, acting as neuroactive
91 metabolites [22]. An impaired intestinal permeability or ‘leaky gut’ could also play a role in the effect
92 of microbiota activity on psychiatric disorders [30,31]. If gut microbial metabolites of potential impact
93 are indeed detectable in blood, this opens the door to blood-based investigations to further study and
94 understand the metabolomic differences between ASD and non-ASD individuals in the context of gut-
95 brain interactions.

96

97 Several studies have reported an altered metabolome associated with ASD during childhood, either in
98 blood [32–35,25,36–44], urine [18,38,45–56] or other matrices [25,57]. However, although some
99 biochemical biomarkers or set of biomarkers seem promising [6], none has yet been proven robust
100 enough for clinical practice. Furthermore, it remains unclear at what point in life biochemical
101 abnormalities of ASD are detectable.

102

103 To study the early role of genetic, prenatal and perinatal variables on disease development, samples
104 need to be collected shortly after birth. However, it is not practically and ethically straightforward to
105 draw blood from newborns prospectively. In many countries, the newborn screening programs are
106 conducted on dried blood spots (DBS) collected a few days after birth. In Denmark, such DBS are
107 stored in the Danish National Biobank and are available for research purposes for the last 30 years,
108 thereby covering approximately half of the country's population [58]. This allows researchers to
109 alleviate the biases inherent to recruitment in prospective clinical studies and instead retrospectively
110 retrieve the samples that are connected to the relevant metadata stored in centralized health registries.

111

112 Taking advantage of this unique resource, we here aimed at studying the strengths and limitations of
113 DBS samples in studying early biochemical abnormalities related to ASD development using an
114 untargeted metabolomics protocol. We compared the metabolomic profiles of newborns that have been
115 diagnosed with ASD at age 7 (cases) to newborns that have not (controls) and investigated potential
116 main confounders.

117

118 **Methods**

119 **Materials and methods**

120 *Materials*

121 Methanol (MeOH), acetonitrile (ACN), isopropanol (IPA), water (H₂O) and formic acid (FA) were of
122 Optima™ LCMS-grade and were purchased from Thermo Fisher Scientific (Waltham, MA, USA).
123 Stable-isotope-labeled internal standards (IS) from the NeoBase Non-derivatized MSMS kit
124 (PerkinElmer, Waltham, MA, USA) were used. The exact list of compounds is provided in Additional
125 file 1.

126

127 *Subjects and samples*

128 Children (n=74) from the iPsych cohort [59] born in 2005 were randomly selected, of which 37 with a
129 diagnosis of autism spectrum disorder (ICD10 F84.0, F84.1, F84.5, F84.8 and/or F84.9) [2] at the date
130 of registry data extraction (2012), and 37 paired controls. Cases and controls were matched based on
131 gender and date of birth. Other metadata such as gestational age (GA), birthweight, age at sampling,
132 month of birth, mother's age at birth, and date of diagnosis, were also collected (when available).

133 Sample size was chosen for several reasons: 1) the unknown variation of metabolites in DBS made
134 power calculations impossible, hence why we needed a pilot study, 2) batch effect is a common
135 technical challenge in metabolomics, and analyzing all samples on one single 96-well plate was
136 expected to reduce technical variability, 3) DBS are highly precious samples.

137 DBS are full blood from newborns, aged between 48 and 72 hours, blotted onto Ahlstrom #226 filter
138 paper and left to dry for at least 3 hours at room temperature before being sent by mail at ambient
139 temperature to the Department of Congenital Disorders at the Statens Serum Institut in Copenhagen.

140 Subsequent to being used in the newborn screening program the samples are biobanked in the Danish
141 National Biobank (www.nationalbiobank.dk) at -20°C until they are retrieved for further research
142 analysis.

143

144 *Sample extraction*

145 A punch of 3.2-mm diameter was collected from each DBS using a Panthera-Puncher™ 9 blood spot
146 punching system (PerkinElmer) directly into a MicroPlate, non-coated 96-well clear polystyrene plate
147 (PerkinElmer). 100 µL of IS in extraction buffer were added to each well. The IS were labelled amino
148 acids (AA IS) and acylcarnitines (AC IS) diluted in 80% methanol (i.e. dilution factor of 1:330,
149 concentrations in Additional file 1). The plate was heat-sealed and shaken for 45 min at 750 rpm at
150 25°C in a PHMP-4 incubator. Then it was centrifuged for 30 min at 4000 rpm at 4 °C.

151 All the transferring steps were performed on a Microlab STAR line automated liquid handling
152 workstation using Venus software (Hamilton, Bonaduz, Switzerland).

153 The supernatant (75 µL) was transferred to a hard-shell 96-well polypropylene PCR plate (Bio-Rad)
154 and dried down with nitrogen 60 L/min at 25 °C for 1 hour on an EVX-192 (Apricot Designs
155 Evaporex). The residue was reconstituted in 75 µL 2.5% methanol, shaken for 15 min at 750 rpm at
156 25°C in a PHMP-4 incubator, and centrifuged 10 min at 4000 rpm at 4 °C. 65µL were transferred to a
157 hard-shell 96-well polypropylene PCR plate (Bio-Rad), heat-sealed, and centrifuged again for 5 min at
158 3000 rpm at 4 °C. The method from sample preparation to MS acquisition is also available as a table
159 according to the guidelines for standardization of LCMS method reporting [60] with adaptation to
160 metabolomics (Additional file 1).

161

162 *Quality assurance*

163 LC-MS/MS instrument performance was controlled by analyzing 4 pooled extracts, 8 solvent blanks,
164 and 3 paper blanks at regular intervals. Pooled extracts were made of 5 µL of reconstituted extract from
165 each of the samples (cases and controls only, total of 370 µL divided in four wells spread across the
166 plate) and were used to assess the consistency of extraction and data acquisition. Solvent blanks were
167 used to check for carry over and instrument noise, while paper blanks were used to monitor matrix
168 signals from the paper. Internal standards were used to control the quality of the extraction, elution, and

169 signal acquisition. Paired cases and controls were injected after one another but in a random order (first
170 case, then control, or vice-versa). Pairs were randomized over the plate.

171

172 *Liquid chromatography*

173 The samples were injected using an autosampler with stack cooler (Open Autosampler UltiMate OAS-
174 3300TXRS (Thermo Fisher Scientific)) and eluted through a Waters Acquity UPLC BEH C18 column
175 (130 Å, 2.1 mm x 50 mm, 1.7-µm particles) preceded by a Waters Acquity UPLC BEH C18 VanGuard
176 pre-column, 130 Å, 2.1 mm x 5 mm, 1.7-µm particles) using a Transcend II, LX-2 with UltiMate
177 pumps (Thermo Fisher Scientific). The pressure limits were set at 0.0 – 1034.0 bar.

178 The mobile phase consisted of solvent A (97.31% H₂O, 1.25% ACN, 1.25% MeOH and 0.2% FA), and
179 B (2.49% H₂O, 48.66% ACN, 48.66% MeOH and 0.2% FA).

180

181 The Wash1 solvent was mobile phase A and the Wash2 solvent mix was 25:25:25:25 v/v
182 MeOH:IPA:H₂O:ACN + 0.2% FA. The gradient (0.25 mL/min) started with 100% A : 0% B. After 0.5
183 min, we applied a gradient ramp to 0% A: 100% B over 8.5 minutes followed by a 0.5-min flow ramp
184 up to 0.9 mL/min and 5 minutes of 100% B. At 15 min, the column was equilibrated for 5.5 min with
185 100% A. At 17.5 min, the flow was changed back to 0.25 mL/min over 0.5 min. The total run time was
186 20.5 minutes, including 10 min sample run time and 10.5 min column wash and equilibration. The
187 column temperature was maintained at 60.0°C using a hot pocket column heater and the samples in the
188 autosampler were kept at 4°C throughout the analysis. The data was acquired in profile mode from 0.20
189 min and over 9.80 min.

190

191 *Mass spectrometry*

192 The Q-Exactive Orbitrap mass spectrometer (Thermo Fisher Scientific) was operated with a heated
193 electrospray ionization source (HESI) in positive mode. The instruments were controlled using
194 TraceFinder 4.1 Clinical Research and Aria MX (Thermo Fisher Scientific). Mass range in MS full
195 scan mode was set to 70 to 1050 m/z with a resolution of 35,000. Automatic gain control was set to
196 1.10^6 , and maximum injection time at 100 ms. For data dependent-MS2 the resolution was set to
197 17,500. Automatic gain control was set to 1.10^5 , and maximum injection time at 50 ms. Loop count
198 was 5, isolation window 1.5 m/z and the stepped NCE 17.5, 35 and 52.5 eV. The spectrum data type
199 was set to Profile. In data dependent settings the Apex trigger was set to 2 to 7 s with 15s dynamic
200 exclusion and charge exclusion on 3-8 and >8. Diisooctylphthalate (391.28429 m/z) was selected as
201 lock mass. Other settings included the sheath gas pressure (N_2 , 32 psi), the auxiliary gas flow and
202 temperature (N_2 , 8 arb. units, 350°C), the S-lens radio frequency level (50.0%), the ion source
203 temperature (350°C), and the spray voltage (3.8 kV between 0-9.8 min and 1.0 kV between 9.8-10
204 min).

205

206 *LC-MS data preprocessing*

207 After conversion to .mzML (centroid) using MSConvertGUI v3.0 (ProteoWizard Software Foundation,
208 Palo Alto, CA, USA) [61], raw files were pre-processed using MZmine v2.41.2 [62,63]. All setting
209 details are provided in the batch .xml file (Additional file 2). Briefly, data were cropped based on
210 retention time (RT) 0.27-9.80 min. Masses were detected with a noise threshold of 10,000 for MS1 and
211 of 0 for MS2. The chromatogram was built using the ADAP module [64], with minimum 7 scans per
212 peak, a group intensity threshold of 10,000, a minimum highest intensity of 150,000, and a m/z
213 tolerance of 0.001 m/z or 5 ppm. Deconvolution was performed using the Wavelets (ADAP) module,
214 with m/z center calculation using median, and ranges for MS2 scan pairing of 0.01 Da and 0.4 min. The
215 isotopes were grouped with a m/z tolerance of 0.001 m/z or 5 ppm and RT tolerance of 0.1 min. Peaks

216 were aligned with a m/z tolerance of 0.001 m/z or 5 ppm and RT tolerance of 0.1 min, with 75% weight
217 given to m/z and 25% to RT. Finally, peaks were filtered with a minimum of fifteen peaks in a row, and
218 the same RT and peak duration ranges as previously applied. The feature quantification table (.csv) and
219 aggregated MS2 masses list (.mgf) were exported (no merging of MS/MS and filter rows: ALL) for
220 further analysis.

221

222 *Feature-based molecular networking using GNPS and compound annotation*

223 A molecular network was created with the feature-based molecular networking workflow ([https://ccms-](https://ccms-ucsd.github.io/GNPSDocumentation/featurebasedmolecularnetworking/)
224 [ucsd.github.io/GNPSDocumentation/featurebasedmolecularnetworking/](https://ccms-ucsd.github.io/GNPSDocumentation/featurebasedmolecularnetworking/)) [65] on the GNPS website
225 (<http://gnps.ucsd.edu>) [66] by uploading the aggregated MS2 mass list. The data was filtered by removing
226 all MS/MS fragment ions within +/- 17 Da of the precursor m/z . MS/MS spectra were window filtered
227 by choosing only the top 6 fragment ions in the +/- 50Da window throughout the spectrum. The precursor
228 ion mass tolerance was set to 0.02 Da and a MS/MS fragment ion tolerance of 0.02 Da. A network was
229 then created where edges were filtered to have a cosine score above 0.7 and more than 4 matched peaks.
230 Further, edges between two nodes were kept in the network if and only if each of the nodes appeared in
231 each other's respective top 10 most similar nodes. Finally, the maximum size of a molecular family was
232 set to 100, and the lowest scoring edges were removed from molecular families until the molecular family
233 size was below this threshold. The spectra in the network were then searched against GNPS' spectral
234 libraries. The library spectra were filtered in the same manner as the input data. All matches kept between
235 network spectra and library spectra were required to have a score above 0.7 and at least 4 matched peaks.
236 The .graphml network file was then visualized using Cytoscape v3.7.2 [67] where individual sample data
237 and metadata were locally plotted (per sample and metadata sample group relative intensities). To
238 enhance annotation of potential compounds of interest using the mzCloud spectral library (Thermo Fisher
239 Scientific), .raw files were also preprocessed using Compound Discoverer 2.1 (CD2.1) SP1 software

240 (Thermo Fisher Scientific). Details regarding the settings are provided in Additional file 3. GNPS and
241 Compound Discoverer (annotation reported when above mzCloud 80% confidence in identity or
242 similarity search) offer annotations with a level 2 confidence according to the Metabolomics Standards
243 Initiative (i.e. putative annotation) [68,69]. To summarize and further enhance chemical structural
244 information within the molecular network, substructure information ([https://ccms-
245 ucsd.github.io/GNPSDocumentation/ms2lda/](https://ccms-ucsd.github.io/GNPSDocumentation/ms2lda/)) [70], information from *in silico* structure annotations from
246 Network Annotation Propagation [71] and Dereplicator [72] were incorporated using the GNPS
247 MolNetEnhancer workflow (<https://ccms-ucsd.github.io/GNPSDocumentation/molnetenhancer/>) [73]
248 with chemical class annotations retrieved from the ClassyFire chemical ontology [74]. When no chemical
249 structural information could be retrieved through the above searches, the MS/MS spectra were
250 additionally searched via MASST [75] and SIRIUS+CSI:FingerID [76–78]. MASST allows to query a
251 single MS/MS spectrum across all public GNPS datasets giving an idea of the type of samples or matrices
252 where the same MS/MS spectrum has been detected [75]. SIRIUS+CSI:FingerID uses deep learning
253 algorithms to predict the molecular and structural formula of a molecule from MS/MS spectra [76–79].

254

255 *Contamination filtering and further data curation*

256 Using a Kendrick Mass Filter, we explored the compositionality of our data to assess the potential
257 presence of undesired chemical background [80]. Out of the 4,360 features obtained through MZmine
258 preprocessing, more than 1,100 possessed repeat units typical of polyethylene glycol (PEG) and
259 polypropylene glycol (PPG). Filtering of PEG followed by filtering of PPG was performed using a
260 Kendrick Mass Filter [80] with the following parameters: number of observed signals = 5, Kendrick
261 mass defect = 0.01, and fraction base = 1 (see Additional file 4AB).

262 Of the 3,253 remaining features, we further excluded those with a maximum intensity in paper blanks /
263 maximum intensity in samples ratio ≥ 0.2 , as well as features with 20% or more gaps (i.e. missing
264 value) in cases and/or in controls (1,975 features filtered).

265

266 *Data visualization and outlier handling*

267 We performed principal coordinates analyses (PCoA) to visualize the data in an interactive 3D-space
268 using EMPEROR within QIIME 2 [81,82] using the Bray-Curtis, Canberra, Robust Aitchison [83] and
269 Jaccard distance metrics. This tool allowed us to easily map metadata on each sample in the 3D-space
270 and quickly detect broad patterns in the data, such as assessing the consistency of repeated pool
271 injections (i.e. repeated injections of the same pooled samples should cluster in PCoA space). When
272 performing these calculations on our “raw” unfiltered feature table (4,360 features), all tested distance
273 metrics showed seven samples as clear outliers, of which two controls and five cases. After
274 contamination filtering and data curation (1,281 features), six outliers remained since one outlier
275 (control) was due to PEG contamination. Among the investigated potential explanations for these
276 outliers, no pattern was found when looking at: position on the plate layout, potential RT shift
277 impairing the alignment, and metadata. However, targeted analysis of labeled internal standards and
278 unlabeled endogenous homologs showed that significant (but unexplained) errors occurred during
279 LCMS acquisition, with many undetectable compounds (TraceFinder 4.1 Clinical Research, Thermo
280 Fischer Scientific) (Additional file 5). A heatmap representation of the data (1,281 features) using
281 MetaboAnalyst 4.0 [84] confirmed the six outliers with very low intensities (Additional file 5).
282 Therefore, we decided to exclude these outliers from further statistical analyses and reran the PCoA
283 calculations on the remaining 68 samples.

284

285 *Statistics*

286 Using the calculated distance matrices from the PCoAs (1,281 features, 68 samples), we performed
287 Permutational Multivariate Analyses of Variance (PERMANOVAs) [85] to assess how much of the
288 variance in the data is explained by a certain variable in the metadata. We investigated the following
289 variables: autism (yes/no), autism subtype, gender, birthweight, gestational age, age at sampling, month
290 of birth, and injection order. The Adonis R^2 value indicates to what extent the variance is explained by
291 the tested variable. Significance threshold was set at 0.05. Calculations were performed using the *vegan*
292 and *ggplot2* packages in R software v3.6.1 [86].
293 Finally, the curated dataset (1,281 features, 68 samples, unpaired samples) was processed using
294 MetaboAnalyst 4.0 [84]. We excluded features with more than 50% missing values and replaced the
295 remaining missing values by a small value (half the minimum positive value in the original data). We
296 further filtered non-informative near-constant features based on interquartile range and applied a glog
297 transformation and Pareto scaling. We used a fold-change threshold of 2 (case/control or control/case)
298 and performed t-test and Wilcoxon rank-sum test with FDR correction for multiple comparisons. We
299 could not reliably use the Partial Least Squares Discriminant Analysis (negative Q2 in cross
300 validation). All Jupyter notebooks used for statistical analysis are publicly available on github.

301

302 **Results**

303 *Subjects*

304 Subjects' characteristics are presented in Table 1 (details in Additional file 6). Cases and controls were
305 similar in terms of GA, birthweight, age at sampling and age of their mother at birth. The most
306 prevalent autism subtype was childhood autism. Most cases had only one diagnosis, but six had both
307 unspecified pervasive development disorder and autism (either childhood autism or atypical autism).
308 None had more than two diagnoses. Median age at first diagnosis was 5.6 years (range 1.1-7.8). Most
309 subjects were born at term ($GA \geq 38$ weeks). Only three cases and two controls were born preterm.

310

311 [Table 1]

312

313 *Molecular Network analysis*

314 From all features for which a MS2 spectrum has been acquired (2217 features over 4360) a feature-
315 based molecular network was computed via GNPS. Annotation could be retrieved for 150 features
316 (3.4%) of which 103 by matching to GNPS libraries (annotation level 2), and 47 by matching to our in-
317 house library using Trace Finder (annotation level 1, Additional file 7). Using the MolNetEnhancer
318 workflow [73], putative chemical structural information at the chemical class level, corresponding to a
319 level 3 annotation, could be retrieved for an additional 859 features. Hence, nearly 46% (1009) of the
320 mass spectral features could be putatively annotated at a level 1 to 3 (Additional file 7). Annotation
321 covered 31 chemical classes including 53 subclasses and 116 direct parents, such as medium-chain
322 fatty acids, phosphatidylcholines, nucleotides, amino acids, bile acids, steroids, acyl carnitines and
323 catecholamines.

324 Molecular families (independent clusters of nodes) from the 15 predominant putatively annotated
325 chemical classes are presented in Figure 1 (see details in Additional file 7). Plotting the average
326 intensities in the three groups (cases, controls, paper blanks) as well as fold change values (or p-values)
327 on the network nodes allowed for a quick overview of the molecular families with potential biological
328 relevance (See the example of bile acids in Figure 2). This analysis showed the potential of DBS in
329 covering various chemical classes and the power of feature-based molecular network analyses and
330 related metabolome mining tools in expanding the interpretability of complex untargeted metabolomics
331 data.

332

333 *Statistical analyses*

334 In PCoA space, repeated pool injections clustered satisfactorily showing that the LC-MS/MS data
335 acquisition was of acceptable quality (Figure 3). When looking at the two groups (cases/controls), no
336 clear separation was observed, even after removal of outliers (Figure 3A) and on all tested distance
337 metrics.

338 The PERMANOVAs (Figure 4, Additional file 8) revealed that the variance in the data was not
339 significantly explained by the grouping (cases/controls) (Bray-Curtis Adonis $R^2 = 0.014$, P-value =
340 0.777), even when distinguishing subtypes of ASD, although subtypes had a higher Adonis R^2 (Bray-
341 Curtis Adonis $R^2 = 0.070$, P-value = 0.707, see Table 1 for details on subtypes of ASD). Similarly, the
342 gender and birthweight did not significantly explain the variance in the data. However, variation in the
343 data explained by gestational age (Bray-Curtis Adonis $R^2 = 0.034$, P-value = 0.028), age at sampling
344 (Bray-Curtis Adonis $R^2 = 0.053$, P-value = 0.002) and especially month of birth (Bray-Curtis Adonis
345 $R^2 = 0.262$, P-value = 0.001, see Figure 3B) was significant, and to an increasing extent respectively
346 (greater Adonis R^2). On a technical level, we also observed a significant effect of injection order on the
347 data variation (Bray-Curtis Adonis $R^2 = 0.047$, P-value = 0.002), pointing to a limitation in our LC-
348 MS/MS method.

349

350 Results of univariate analyses and fold change analysis were carefully scrutinized feature by feature.
351 Considering our small sample size and potential pitfalls inherent to untargeted metabolomics related to
352 contaminants or integration errors, we thought essential to inspect each result to eliminate false
353 positives and spurious findings. Our inspection consisted of a five-step logic starting with peak
354 integration and shape quality (MZmine). We then plotted all individual intensity values to assess
355 whether the case/control difference was driven by four or fewer samples. If not, we reported the extent
356 of missing values in each group, checked the consistency of replicated pool injections, and finally
357 checked whether the feature was present in the feature-based molecular network, annotated as a

358 contaminant or in a node cluster with such annotation (Additional file 9). A large proportion of the
359 inspected features were excluded based on these criteria, showing the importance of such a verification
360 in order not to pursue spurious findings in future studies.

361 Among the 24 features with a fold change (case/control) value <0.5 or >2.0 , only one passed manual
362 inspection (Table 2, the full table is in Additional file 9). Eluting quite late (RT = 6.64 min, ID8605),
363 this relatively hydrophobic compound had a detected m/z of 1014.4892 and was not connected to any
364 other node in the network analysis (see its mass spectrum in Additional file 10). It could not be
365 annotated, but the algorithm of SIRIUS+CSI:FingerID pointed at a raw formula of $C_{36}H_{63}N_{21}O_{14}$
366 ($[M+H]^+$, only 7.12% scoring). This compound was more than twice as intense in controls as in cases
367 (FC 0.42, average intensity in cases $2.73E+05$ and controls $7.51E+05$), and would need further
368 investigation, especially as it was not detected in many samples (Additional file 9). A MASST search
369 was performed, however the feature with m/z 1014.4892 was not found in any of the public datasets on
370 GNPS.

371

372 [Table 2]

373

374 No feature was significantly differentially abundant in cases and controls according to the univariate
375 analyses with FDR correction for multiple comparisons (p values in Table 2).

376 Features that were differentially abundant before FDR correction are presented in Table 2. As a high
377 proportion of features were deemed irrelevant after inspection, we are presenting only the two relevant
378 features that passed our quality-control criteria. The full list and inspection details can be found in
379 Additional file 9. Methacholine was found to be significantly more abundant in cases when compared
380 to controls (average intensity in cases $4.41E+07$ and controls $3.94E+07$) both when using a t-test (p =
381 0.0021) and a Wilcoxon rank-sum test (p = 0.0031). The corresponding node (ID159) in the network

382 analysis was connected to another node with a mass difference of $-0.036 m/z$ (225 ppm) which could
383 not be annotated. None of the applied metabolome mining tools was able to retrieve chemical structural
384 information for the second compound significantly more abundant in cases than in controls (ID5593,
385 m/z 1014.4892, average intensity in cases $5.71E+05$ and controls $4.35E+05$). SIRIUS+CSI:Finger ID
386 predicted a molecular formula of $C_{11}H_{22}N_2O_3$ (M+H⁺, 99.96% scoring). Its RT of 2.78 min could
387 indicate a medium polarity with a logP between -1.0 and 0.5 when compared to tryptophan (RT 2.56
388 min, HMDB experimental logP -1.06) and hippuric acid (RT 3.04 min, HMDB experimental logP
389 0.31).

390 Among the 273 compounds reported in two recent reviews [6,87], 22 were cited at least three times, of
391 which 18 could be linked to features in our study after manual verification (Table 3, Additional file 11).

392

393 [Table 3]

394

395 **Discussion**

396 To assess the early signs of ASD development shortly after birth, we compared DBS samples from
397 newborns that have later on been diagnosed with ASD to newborns that have not. Our pilot study
398 showed the capacity of untargeted metabolomics as an analytical tool applied to biobanked DBS
399 samples to cover several metabolites relevant to ASD, thus suggesting that biochemical markers of
400 ASD are present at birth and could be targeted during neonatal screening. In addition, our method
401 pinpointed other factors which have a strong influence on the metabolic profile of newborn DBS, such
402 as gestational age, age at sampling and month of birth, and which are important to consider when
403 designing metabolomic studies in neonatal, biobanked DBS.

404 One study from 2013 was performed on newborn DBS samples from 16 autistic children and assessed
405 90 biomarkers (not only small molecules) using immunoassays [88] of which three sets of five were
406 associated with ASD. Another study was performed on DBS but in ASD children (n=83, age 2-10
407 years) and was targeting 45 metabolites [37], of which 9 were significantly higher in ASD children.
408 However, the potential of DBS in *untargeted* metabolomics studies has not yet been fully studied, and
409 never in the context of ASD (see recent reviews [6,87]).

410 Among the 22 compounds that had been repeatedly (≥ 3 times) reported in the literature to be involved
411 in ASD, 18 could be putatively annotated in our study, showing that our analytical pipeline covers
412 many relevant metabolites, including some specific to gut microbiota activity. Despite thorough
413 curation and inspection of the acquired data, no feature was significantly differentially abundant in
414 cases and controls after FDR correction. The small sample size as well as strong confounders could
415 play a role in the low power of this pilot study. Nonetheless, the PERMANOVA results showed that
416 subtypes of autism seemed to explain more variance in the data than just the case/control division
417 (higher Adonis R^2 , Figure 4). This could mean that subtypes have indeed distinct biochemical profiles
418 and should maybe be considered separately or in a stratified manner. Although, the lack of significance
419 could suggest that ASD genetic, prenatal and/or perinatal variables do not (sufficiently) translate into
420 biochemical abnormalities in newborns or that these are not detectable in biobanked DBS using our
421 current experimental setup, we were able to pinpoint 18 out of 22 metabolic markers associated with
422 ASD in previous studies. This finding suggests that rather the sample size and confounders are
423 responsible for the absent signal observed here, and future studies controlling for the here identified
424 confounders and greater sample size could provide more answers.

425

426 Among the hits and interesting findings of our pilot, we could show that a methacholine structural
427 analogue could be a relevant marker for ASD, as it was found at a higher although not significant

428 abundance in newborns that have been diagnosed with ASD at age 7. Methacholine is a choline ester
429 drug acting as non-selective muscarinic receptor agonist. It is mainly known as methacholine chloride
430 for its use in assessing bronchial hyper-reactivity in asthmatic patients. Although muscarinic receptors
431 were not associated with autism in children [89], lower estimates of ASD risk among children exposed
432 during fetal life to muscarinic receptor 2 agonists were reported [90]. Higher abundance of
433 methacholine in DBS of ASD cases, as seen in our study, would therefore not be easily explained and
434 demand further investigation. However, detecting a drug metabolite such as methacholine in newborn
435 samples is unexpected, thus it is more likely that this feature is an endogenous choline ester with
436 similar fragmentation behavior to methacholine.

437

438 Two other unknown features would benefit from being monitored in future studies. One relatively
439 hydrophobic compound (ID8605, m/z 1014.4892) showed an important fold change (much lower in
440 cases) but was not detected in many samples maybe due to low intensities. The second compound
441 (moderately polar, ID5593, m/z 1014.4892, $C_{11}H_{22}N_2O_3$) was significantly higher in cases before FDR
442 correction and detected in more than 65% of samples. Including both in an inclusion list for optimized
443 MS2 acquisition could provide higher quality spectra for better annotation. Overall, we observed poor
444 fragmentation of some analytes (4 fragmentation peaks or less) and optimization of fragmentation
445 parameters to a few targeted compounds, could enable better chemical structural annotation, although
446 fragmentation parameters such as other technical and sample preparation parameters, can never be
447 optimized for all compounds equally.

448

449 Although our study was not designed specifically to assess the tested confounders, we have shown that
450 gestational age, age at sampling and month of birth are strong drivers of metabolomic profiles in

451 newborns. This demonstrates the importance of considering these confounders when designing a future
452 study in newborn DBS.

453

454 Prematurity has been involved in numerous adverse health outcomes [91] and metabolic maturity has
455 been shown to be reflected in the blood and other matrices of infants after birth [92,93]. Although, in
456 the present study, only three cases and two controls were premature (<38 weeks of gestational age), we
457 saw a significant effect of gestational age on the metabolomic profile of newborns thus showing that
458 gestational age is an important factor be controlled for in newborn DBS studies.

459

460 Similarly, we found that age at sampling has a significant impact on the newborn blood metabolome.
461 From 3 to 10 days of age, only one week has passed, and yet fundamental metabolic changes occur in
462 the newborn who is not anymore connected to his/her mother's blood, but exposed to various types of
463 nutrition and environmental conditions (healthcare, hospital vs home, etc.). The endogenous
464 anabolism/catabolism balance is in itself a strong variable to consider at that age. From 2009 onwards,
465 the Danish newborn screening program has indeed chosen to standardize the age at DBS sampling to
466 48 to 72 hours to optimize the window where potential inborn errors of metabolism would be detected
467 best and as early as possible since quick intervention is essential in such cases [94]. The iPsych cohort
468 was based on diagnoses of psychiatric disorders recorded in Danish health registry in 2012 [59]. Such
469 diagnoses are often given after several years of age, which is why the cohort did not cover subjects
470 born after 2005, year at which the age at sampling was not so narrowly standardized. The large sample
471 size of the iPsych cohort (almost 15,000 cases of ASD) should however allow for stricter selection
472 criteria in our future studies.

473

474 Another major change that occurs in newborns at birth and in the following days is the gut maturation
475 and its further colonization by microbes [95]. This topic has been under expanding attention in the last
476 decade, and the development and involvement of gut microbiota in neurodevelopment is being
477 scrutinized extensively [22]. The exact dynamics of the microbiota development in the placenta and
478 during the first days of life is still uncertain [95–97], as well as to what extent its activity can be
479 reflected in the blood. A recent study has shown that gut microbial alpha-diversity can be predicted
480 from the human blood metabolome [98] suggesting that microbial metabolites
481 explain a significant amount of the variance in the human blood metabolome. Thus, although sampled
482 at an early stage in life, it is plausible that microbial metabolites mediating health may be found in
483 dried blood spots from newborns [93]. Studying both fecal and blood samples will be essential to
484 answer questions related to the impact of gut microbes on the gut-brain axis, especially in the context
485 of psychiatric disorders where the brain is the main organ concerned but indeed located quite far from
486 the gut. Microbial metabolites would necessarily need to travel in the blood (or lymph) and through the
487 blood-brain barrier to interact with the brain. In our study, some detected metabolites could partly
488 derive from gut microbiota activity such as DL-Indole-3-lactic acid (ID3461, [99,100]), taurine (ID428,
489 level 3, [25]), various bile acids (Additional file 7, [57]), or inosine 5'-monophosphate (ID1133, level
490 3, [29]).

491

492 Lastly, we found that month of birth explains a significant variation in metabolomic profiles of
493 newborns (Figure 3b, Figure 4). Whether there is a yearly cyclic pattern or whether our findings are
494 specific to 2005 remains to be determined. Explanations could include aspects related to pregnancy
495 conditions varying along the year such as diet, weather conditions and sun exposure (e.g. impact on
496 vitamin D levels, type and extent of physical and social activities, mood and stress [101]), exposure to
497 “seasonal” infectious diseases (e.g. influenza), exposure to varying air quality (e.g. pollution or pollens

498 [102]), as well as storing conditions which might fluctuate over the year (e.g. sample transport at higher
499 temperatures during summer).

500

501 Gender and birthweight were not found to explain a significant part of the variance in the metabolomic
502 profiles of newborns in our study, despite the obvious connection between gestational age and
503 birthweight. The gender misbalance which reflects the gender disparity in ASD (a quarter were girls),
504 non-dedicated design, and small sample size could explain this finding. Some studies have indeed
505 reported that the profile of newborn girls and boys differed in, for instance, blood amino acids and
506 acylcarnitines [103], as well as urine profiles [104]. Despite our finding, we believe that gender and
507 birthweight should be adjusted for and taken into consideration when designing metabolomics studies
508 in newborns. Several of the tested confounders are inter-connected with, for instance, reports of more
509 males being born preterm [105] and females being born lighter [106], both associations being explained
510 by mechanisms that are likely to be reflected in the metabolome such as inflammatory response and
511 insulin resistance, respectively.

512

513 On the technical side, the strong effect of injection order is again a reminder that randomizing sample
514 pairs on the plates is fundamental in untargeted metabolomics. Although technical improvements can
515 be considered, it is extremely difficult if not impossible to avoid some level of signal drift and
516 carryover in untargeted metabolomics studies[107].

517

518 **Limitations and strengths**

519 To avoid batch effect and minimize the use of highly valuable and rare samples, we analyzed only 37
520 pairs of cases and controls in this pilot study. Despite the small sample size that did not confer enough
521 statistical power for pinpointing strong marker metabolites of ASD, we could detect numerous

522 metabolites associated with ASD in previous studies and identify a number of confounders to be
523 considered in future untargeted metabolomics study using newborn DBS. Other confounders not
524 evaluated in our study will need to be assessed in future studies, including metabolic changes in DBS
525 associated with time and storage conditions. Hematocrit variation could not be measured in our study
526 as we had access to only one punch of paper and did not have the possibility to measure a surrogate
527 marker such as potassium [108]. Furthermore, metabolites detected in this study are inherently
528 reflective of sampling protocols, including extraction protocols and MS acquisition parameters and
529 should be interpreted within these limitations.

530

531 **Conclusions**

532 This is the first study assessing metabolomic profiles of a psychiatric disorder, ASD in biobanked,
533 newborn DBS samples. The development of biobanks and reuse of systematically collected DBS
534 samples for research purposes in connection with registry data represent many new opportunities to
535 study the physiopathology and early signs of diseases, with extraordinary impacts in prevention,
536 diagnosis and treatment strategies. We showed that untargeted metabolomics on DBS samples offers a
537 wide and relevant coverage of metabolites for the study of ASD and that the new processing tools used
538 in our method largely expand the interpretability of such complex data.

539

540 **Declarations**

- 541 • Ethics approval and consent to participate

542 The Danish ethical committee approved the project (1-10-72-287-12). All blood samples can be stored
543 without explicit informed consent according to Danish law, and be reused for additional analysis
544 provided that projects are approved by the Research Ethics Committee and the Danish Data Protection
545 Agency. Although research projects require informed consent, the Research Ethics Committee can

546 waive this requirement if samples are anonymously processed, and if the projects do not imply any
547 health-related risk or burden to the subjects [109].

548

549 • Consent for publication

550 Not applicable

551

552 • Availability of data and materials

553 The datasets generated and/or analyzed during the current study are not publicly available due to the
554 risk of compromising individual privacy but are available from the corresponding author on reasonable
555 request and provided that an appropriate collaboration agreement can be agreed upon.

556

557 • Competing interests

558 The authors declare that they have no competing interests.

559

560 • Funding

561 This study was funded by The Lundbeck Foundation, Denmark.

562 This research has been conducted using the Danish National Biobank resource supported by the Novo
563 Nordisk Foundation grant number is 2010-11-12 and 2009-07-28.

564

565 *Disclaimer*

566 This funder had no involvement in any aspect of the study.

567

568 *Grant number*

569 R248-2017-2003 - Period III: 1 March 2018 - 28 February 2021

570 R155-2014-1724: Period II: 1 March 2015 – 28 February 2018

571 R102-A9118: Period I: 1 March 2012 – 28 February 2015

572

573 • Authors' contributions

574 JC and AC designed the study.

575 SSL collected the samples and ran the metabolomics analyses.

576 ME defined and coded major steps of data processing, chemical structural annotation and statistical
577 analysis and edited the manuscript.

578 JC processed the data, performed statistical analyses, and drafted the manuscript.

579 All authors were involved in the manuscript edition and data interpretation, critically revised the
580 manuscript for important intellectual content, and approved the final version of this manuscript.

581 JC and AC had full access to all the data in the study and take responsibility for the integrity of the data
582 and the accuracy of the data analysis.

583

584 • Acknowledgements

585 We thank Anders Björkbom for his major contribution to the LCMS method development and Marie
586 Bækvad-Hansen for her help in curating data.

587

588 • Authors' information (optional)

589 Not applicable

590

591

592 **References**

593 1. Randall M, Egberts KJ, Samtani A, Scholten RJ, Hooft L, Livingstone N, et al. Diagnostic tests for autism
594 spectrum disorder (ASD) in preschool children. *Cochrane Database Syst Rev.* 2018;

595 2. World Health Organization. *The ICD-10 classification of mental and behavioural disorders: diagnostic criteria
596 for research.* Geneva: World Health Organization; 1993.

597 3. Adam D. Mental health: On the spectrum. *Nat News.* 2013;496:416.

598 4. Frances A. ICD, DSM and The Tower of Babel. *Aust N Z J Psychiatry.* 2014;48:371–3.

599 5. Bejarano-Martín Á, Canal-Bedia R, Magán-Maganto M, Fernández-Álvarez C, Cilleros-Martín MV, Sánchez-
600 Gómez MC, et al. Early Detection, Diagnosis and Intervention Services for Young Children with Autism
601 Spectrum Disorder in the European Union (ASDEU): Family and Professional Perspectives. *J Autism Dev
602 Disord.* 2019;

- 603 6. Shen L, Liu X, Zhang H, Lin J, Feng C, Iqbal J. Biomarkers in autism spectrum disorders: Current progress.
604 *Clin Chim Acta Int J Clin Chem.* 2019;502:41–54.
- 605 7. Bai D, Yip BHK, Windham GC, Sourander A, Francis R, Yoffe R, et al. Association of Genetic and
606 Environmental Factors With Autism in a 5-Country Cohort. *JAMA Psychiatry.* 2019;76:1035–43.
- 607 8. Grove J, Ripke S, Als TD, Mattheisen M, Walters RK, Won H, et al. Identification of common genetic risk
608 variants for autism spectrum disorder. *Nat Genet.* 2019;51:431–44.
- 609 9. Newschaffer CJ, Croen LA, Daniels J, Giarelli E, Grether JK, Levy SE, et al. The epidemiology of autism
610 spectrum disorders. *Annu Rev Public Health.* 2007;28:235–58.
- 611 10. Hannon E, Schendel D, Ladd-Acosta C, Grove J, Hansen CS, Andrews SV, et al. Elevated polygenic burden
612 for autism is associated with differential DNA methylation at birth. *Genome Med.* 2018;10.
- 613 11. Braam W, Ehrhart F, Maas APHM, Smits MG, Curfs L. Low maternal melatonin level increases autism
614 spectrum disorder risk in children. *Res Dev Disabil.* 2018;82:79–89.
- 615 12. Abbott PW, Gumusoglu SB, Bittle J, Beversdorf DQ, Stevens HE. Prenatal stress and genetic risk: How
616 prenatal stress interacts with genetics to alter risk for psychiatric illness. *Psychoneuroendocrinology.* 2018;90:9–
617 21.
- 618 13. Fine R, Zhang J, Stevens HE. Prenatal stress and inhibitory neuron systems: implications for
619 neuropsychiatric disorders. *Mol Psychiatry.* 2014;19:641–51.
- 620 14. Croen LA, Qian Y, Ashwood P, Zerbo O, Schendel D, Pinto-Martin J, et al. Infection and Fever in
621 Pregnancy and Autism Spectrum Disorders: Findings from the Study to Explore Early Development. *Autism*
622 *Res.* 2019;12:1551–61.
- 623 15. Kuzniewicz MW, Wi S, Qian Y, Walsh EM, Armstrong MA, Croen LA. Prevalence and Neonatal Factors
624 Associated with Autism Spectrum Disorders in Preterm Infants. *J Pediatr.* 2014;164:20–5.
- 625 16. Apgar V. A proposal for a new method of evaluation of the newborn infant. *Curr Res Anesth Analg.*
626 1953;32:260–7.
- 627 17. Modabbernia A, Sandin S, Gross R, Leonard H, Gissler M, Parner ET, et al. Apgar score and risk of autism.
628 *Eur J Epidemiol.* 2019;34:105–14.
- 629 18. Alberti A, Pirrone P, Elia M, Waring RH, Romano C. Sulphation deficit in “low-functioning” autistic
630 children: a pilot study. *Biol Psychiatry.* 1999;46:420–4.
- 631 19. Chaidez V, Hansen RL, Hertz-Picciotto I. Gastrointestinal problems in children with autism, developmental
632 delays or typical development. *J Autism Dev Disord.* 2014;44:1117–27.
- 633 20. Krajmalnik-Brown R, Lozupone C, Kang D-W, Adams JB. Gut bacteria in children with autism spectrum
634 disorders: challenges and promise of studying how a complex community influences a complex disease. *Microb*
635 *Ecol Health Dis.* 2015;26.
- 636 21. White JF. Intestinal pathophysiology in autism. *Exp Biol Med* Maywood NJ. 2003;228:639–49.

- 637 22. Cerdó T, Diéguez E, Campoy C. Early nutrition and gut microbiome: interrelationship between bacterial
638 metabolism, immune system, brain structure, and neurodevelopment. *Am J Physiol-Endocrinol Metab.*
639 2019;317:E617–30.
- 640 23. Wang S, Harvey L, Martin R, van der Beek EM, Knol J, Cryan JF, et al. Targeting the gut microbiota to
641 influence brain development and function in early life. *Neurosci Biobehav Rev.* 2018;95:191–201.
- 642 24. De Angelis M, Francavilla R, Piccolo M, De Giacomo A, Gobbetti M. Autism spectrum disorders and
643 intestinal microbiota. *Gut Microbes.* 2015;6:207–13.
- 644 25. Sharon G, Cruz NJ, Kang D-W, Gandal MJ, Wang B, Kim Y-M, et al. Human Gut Microbiota from Autism
645 Spectrum Disorder Promote Behavioral Symptoms in Mice. *Cell.* 2019;177:1600-1618.e17.
- 646 26. Kelly RS, Boulin A, Laranjo N, Lee-Sarwar K, Chu SH, Yadama AP, et al. Metabolomics and
647 Communication Skills Development in Children; Evidence from the Ages and Stages Questionnaire.
648 *Metabolites.* 2019;9:42.
- 649 27. Sgritta M, Dooling SW, Buffington SA, Momin EN, Francis MB, Britton RA, et al. Mechanisms Underlying
650 Microbial-Mediated Changes in Social Behavior in Mouse Models of Autism Spectrum Disorder. *Neuron.*
651 2019;101:246-259.e6.
- 652 28. Adams JB, Borody TJ, Kang D-W, Khoruts A, Krajmalnik-Brown R, Sadowsky MJ. Microbiota transplant
653 therapy and autism: lessons for the clinic. *Expert Rev Gastroenterol Hepatol.* 2019;13:1033–7.
- 654 29. Adams JB, Vargason T, Kang D-W, Krajmalnik-Brown R, Hahn J. Multivariate Analysis of Plasma
655 Metabolites in Children with Autism Spectrum Disorder and Gastrointestinal Symptoms Before and After
656 Microbiota Transfer Therapy. *Processes.* 2019;7:806.
- 657 30. Borre YE, O’Keefe GW, Clarke G, Stanton C, Dinan TG, Cryan JF. Microbiota and neurodevelopmental
658 windows: implications for brain disorders. *Trends Mol Med.* 2014;20:509–18.
- 659 31. Magistris L de, Familiari V, Pascotto A, Sapone A, Frolli A, Iardino P, et al. Alterations of the Intestinal
660 Barrier in Patients With Autism Spectrum Disorders and in Their First-degree Relatives. *J Pediatr Gastroenterol*
661 *Nutr.* 2010;51:418–24.
- 662 32. Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma Amino Acid Levels in Children with Autism and
663 Their Families. *J Autism Dev Disord.* 2003;33:93–7.
- 664 33. Evans C, Dunstan RH, Rothkirch T, Roberts TK, Reichelt KL, Cosford R, et al. Altered amino acid excretion
665 in children with autism. *Nutr Neurosci.* 2008;11:9–17.
- 666 34. De Angelis M, Piccolo M, Vannini L, Siragusa S, De Giacomo A, Serrazanetti DI, et al. Fecal Microbiota
667 and Metabolome of Children with Autism and Pervasive Developmental Disorder Not Otherwise Specified. *Plos*
668 *One.* 2013;8:e76993.
- 669 35. Kang D-W, Ilhan ZE, Isern NG, Hoyt DW, Howsmon DP, Shaffer M, et al. Differences in fecal microbial
670 metabolites and microbiota of children with autism spectrum disorders. *Anaerobe.* 2018;49:121–31.
- 671 36. Naushad SM, Jain JMN, Prasad CK, Naik U, Akella RRD. Autistic children exhibit distinct plasma amino
672 acid profile. *Indian J Biochem Biophys.* 2013;50:474–8.

- 673 37. Barone R, Alaimo S, Messina M, Pulvirenti A, Bastin J, Group M-A, et al. A Subset of Patients With Autism
674 Spectrum Disorders Show a Distinctive Metabolic Profile by Dried Blood Spot Analyses. *Front Psychiatry*.
675 2018;9.
- 676 38. Anwar A, Abruzzo PM, Pasha S, Rajpoot K, Bolotta A, Ghezzi A, et al. Advanced glycation endproducts,
677 dityrosine and arginine transporter dysfunction in autism - a source of biomarkers for clinical diagnosis. *Mol*
678 *Autism*. 2018;9:3.
- 679 39. Smith AM, King JJ, West PR, Ludwig MA, Donley ELR, Burrier RE, et al. Amino Acid Dysregulation
680 Metabotypes: Potential Biomarkers for Diagnosis and Individualized Treatment for Subtypes of Autism
681 Spectrum Disorder. *Biol Psychiatry*. 2019;85:345–54.
- 682 40. West PR, Amaral DG, Bais P, Smith AM, Egnash LA, Ross ME, et al. Metabolomics as a Tool for
683 Discovery of Biomarkers of Autism Spectrum Disorder in the Blood Plasma of Children. *PLoS ONE*. 2014;9.
- 684 41. Rangel-Huerta OD, Gomez-Fernández A, de la Torre-Aguilar MJ, Gil A, Perez-Navero JL, Flores-Rojas K,
685 et al. Metabolic profiling in children with autism spectrum disorder with and without mental regression:
686 preliminary results from a cross-sectional case-control study. *Metabolomics Off J Metabolomic Soc*. 2019;15:99.
- 687 42. Bitar T, Mavel S, Emond P, Nadal-Desbarats L, Lefèvre A, Mattar H, et al. Identification of metabolic
688 pathway disturbances using multimodal metabolomics in autistic disorders in a Middle Eastern population. *J*
689 *Pharm Biomed Anal*. 2018;152:57–65.
- 690 43. Delaye J-B, Patin F, Lagrue E, Le Tilly O, Bruno C, Vuillaume M-L, et al. Post hoc analysis of plasma
691 amino acid profiles: towards a specific pattern in autism spectrum disorder and intellectual disability. *Ann Clin*
692 *Biochem*. SAGE Publications; 2018;55:543–52.
- 693 44. Kuwabara H, Yamasue H, Koike S, Inoue H, Kawakubo Y, Kuroda M, et al. Altered Metabolites in the
694 Plasma of Autism Spectrum Disorder: A Capillary Electrophoresis Time-of-Flight Mass Spectroscopy Study.
695 *PLoS ONE*. 2013;8.
- 696 45. Retey J. The Urocanase Story: A Novel Role of NAD⁺ as Electrophile. *Arch Biochem Biophys*. 1994;314:1–
697 16.
- 698 46. Shaw W. Increased urinary excretion of a 3-(3-hydroxyphenyl)-3-hydroxypropionic acid (HPHPA), an
699 abnormal phenylalanine metabolite of *Clostridia* spp. in the gastrointestinal tract, in urine samples from patients
700 with autism and schizophrenia. *Nutr Neurosci*. 2010;13:135–43.
- 701 47. Mavel S, Nadal-Desbarats L, Blasco H, Bonnet-Brilhault F, Barthélémy C, Montigny F, et al. 1H-13C NMR-
702 based urine metabolic profiling in autism spectrum disorders. *Talanta*. 2013;114:95–102.
- 703 48. Yap IKS, Angley M, Veselkov KA, Holmes E, Lindon JC, Nicholson JK. Urinary metabolic phenotyping
704 differentiates children with autism from their unaffected siblings and age-matched controls. *J Proteome Res*.
705 2010;9:2996–3004.
- 706 49. Ming X, Stein TP, Barnes V, Rhodes N, Guo L. Metabolic perturbation in autism spectrum disorders: a
707 metabolomics study. *J Proteome Res*. 2012;11:5856–62.
- 708 50. Liu A, Zhou W, Qu L, He F, Wang H, Wang Y, et al. Altered Urinary Amino Acids in Children With Autism
709 Spectrum Disorders. *Front Cell Neurosci*. 2019;13.

- 710 51. Kałużna-Czaplińska J. Noninvasive urinary organic acids test to assess biochemical and nutritional
711 individuality in autistic children. *Clin Biochem.* 2011;44:686–91.
- 712 52. Lussu M, Noto A, Masili A, Rinaldi AC, Dessì A, Angelis MD, et al. The urinary ¹H-NMR metabolomics
713 profile of an Italian autistic children population and their unaffected siblings. *Autism Res.* 2017;10:1058–66.
- 714 53. Chen Q, Qiao Y, Xu X, You X, Tao Y. Urine Organic Acids as Potential Biomarkers for Autism-Spectrum
715 Disorder in Chinese Children. *Front Cell Neurosci.* 2019;13.
- 716 54. Emond P, Mavel S, Aïdoud N, Nadal-Desbarats L, Montigny F, Bonnet-Brilhault F, et al. GC-MS-based
717 urine metabolic profiling of autism spectrum disorders. *Anal Bioanal Chem.* 2013;405:5291–300.
- 718 55. Noto A, Fanos V, Barberini L, Grapov D, Fattuoni C, Zaffanello M, et al. The urinary metabolomics profile
719 of an Italian autistic children population and their unaffected siblings. *J Matern Fetal Neonatal Med.*
720 2014;27:46–52.
- 721 56. Gevi F, Zolla L, Gabriele S, Persico AM. Urinary metabolomics of young Italian autistic children supports
722 abnormal tryptophan and purine metabolism. *Mol Autism.* 2016;7:47.
- 723 57. Wang M, Wan J, Rong H, He F, Wang H, Zhou J, et al. Alterations in Gut Glutamate Metabolism Associated
724 with Changes in Gut Microbiota Composition in Children with Autism Spectrum Disorder. *mSystems. American*
725 *Society for Microbiology Journals;* 2019;4.
- 726 58. Nørgaard-Pedersen B, Hougaard DM. Storage policies and use of the Danish Newborn Screening Biobank. *J*
727 *Inherit Metab Dis.* 2007;30:530–6.
- 728 59. Pedersen CB, Bybjerg-Grauholm J, Pedersen MG, Grove J, Agerbo E, Bækvad-Hansen M, et al. The
729 iPSYCH2012 case-cohort sample: new directions for unravelling genetic and environmental architectures of
730 severe mental disorders. *Mol Psychiatry.* 2018;23:6–14.
- 731 60. Vogeser M, Schuster C, Rockwood AL. A proposal to standardize the description of LC-MS-based
732 measurement methods in laboratory medicine. *Clin Mass Spectrom.* 2019;13:36–8.
- 733 61. Chambers MC, Maclean B, Burke R, Amodei D, Ruderman DL, Neumann S, et al. A cross-platform toolkit
734 for mass spectrometry and proteomics. *Nat Biotechnol.* 2012;30:918–20.
- 735 62. Katajamaa M, Miettinen J, Oresic M. MZmine: toolbox for processing and visualization of mass
736 spectrometry based molecular profile data. *Bioinforma Oxf Engl.* 2006;22:634–6.
- 737 63. Pluskal T, Castillo S, Villar-Briones A, Orešič M. MZmine 2: Modular framework for processing,
738 visualizing, and analyzing mass spectrometry-based molecular profile data. *BMC Bioinformatics.* 2010;11:395.
- 739 64. Myers OD, Sumner SJ, Li S, Barnes S, Du X. One Step Forward for Reducing False Positive and False
740 Negative Compound Identifications from Mass Spectrometry Metabolomics Data: New Algorithms for
741 Constructing Extracted Ion Chromatograms and Detecting Chromatographic Peaks. *Anal Chem.* 2017;89:8696–
742 703.
- 743 65. Nothias LF, Petras D, Schmid R, Dührkop K, Rainer J, Sarvepalli A, et al. Feature-based Molecular
744 Networking in the GNPS Analysis Environment. *bioRxiv.* 2019;812404.

- 745 66. Wang M, Carver JJ, Phelan VV, Sanchez LM, Garg N, Peng Y, et al. Sharing and community curation of
746 mass spectrometry data with Global Natural Products Social Molecular Networking. *Nat Biotechnol.*
747 2016;34:828–37.
- 748 67. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment
749 for integrated models of biomolecular interaction networks. *Genome Res.* 2003;13:2498–504.
- 750 68. Schrimpe-Rutledge AC, Codreanu SG, Sherrod SD, McLean JA. Untargeted Metabolomics Strategies—
751 Challenges and Emerging Directions. *J Am Soc Mass Spectrom.* 2016;27:1897–905.
- 752 69. Sumner LW, Amberg A, Barrett D, Beale MH, Beger R, Daykin CA, et al. Proposed minimum reporting
753 standards for chemical analysis: Chemical Analysis Working Group (CAWG) Metabolomics Standards Initiative
754 (MSI). *Metabolomics.* 2007;3:211–21.
- 755 70. Hooft JJJ van der, Wandy J, Barrett MP, Burgess KEV, Rogers S. Topic modeling for untargeted
756 substructure exploration in metabolomics. *Proc Natl Acad Sci.* 2016;113:13738–43.
- 757 71. Silva RR da, Wang M, Nothias L-F, Hooft JJJ van der, Caraballo-Rodríguez AM, Fox E, et al. Propagating
758 annotations of molecular networks using in silico fragmentation. *PLOS Comput Biol.* 2018;14:e1006089.
- 759 72. Mohimani H, Gurevich A, Mikheenko A, Garg N, Nothias L-F, Ninomiya A, et al. Dereplication of peptidic
760 natural products through database search of mass spectra. *Nat Chem Biol.* 2017;13:30–7.
- 761 73. Ernst M, Kang KB, Caraballo-Rodríguez AM, Nothias L-F, Wandy J, Chen C, et al. MolNetEnhancer:
762 Enhanced Molecular Networks by Integrating Metabolome Mining and Annotation Tools. *Metabolites.*
763 2019;9:144.
- 764 74. Djoumbou Feunang Y, Eisner R, Knox C, Chepelev L, Hastings J, Owen G, et al. ClassyFire: automated
765 chemical classification with a comprehensive, computable taxonomy. *J Cheminformatics.* 2016;8:61.
- 766 75. Wang M, Jarmusch AK, Vargas F, Aksenov AA, Gauglitz JM, Weldon K, et al. Mass spectrometry searches
767 using MASST. *Nat Biotechnol.* 2020;38:23–6.
- 768 76. Böcker S, Dührkop K. Fragmentation trees reloaded. *J Cheminformatics.* 2016;8:5.
- 769 77. Dührkop K, Shen H, Meusel M, Rousu J, Böcker S. Searching molecular structure databases with tandem
770 mass spectra using CSI:FingerID. *Proc Natl Acad Sci U S A.* 2015;112:12580–5.
- 771 78. Dührkop K, Fleischauer M, Ludwig M, Aksenov AA, Melnik AV, Meusel M, et al. SIRIUS 4: a rapid tool
772 for turning tandem mass spectra into metabolite structure information. *Nat Methods.* 2019;16:299–302.
- 773 79. Shen H, Dührkop K, Böcker S, Rousu J. Metabolite identification through multiple kernel learning on
774 fragmentation trees. *Bioinforma Oxf Engl.* 2014;30:i157-164.
- 775 80. da Silva RR, Vargas F, Ernst M, Nguyen NH, Bolleddu S, del Rosario KK, et al. Computational Removal of
776 Undesired Mass Spectral Features Possessing Repeat Units via a Kendrick Mass Filter. *J Am Soc Mass*
777 *Spectrom.* 2019;30:268–77.
- 778 81. Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, et al. Reproducible, interactive,
779 scalable and extensible microbiome data science using QIIME 2. *Nat Biotechnol.* 2019;37:852–7.

- 780 82. Vázquez-Baeza Y, Pirrung M, Gonzalez A, Knight R. EMPERor: a tool for visualizing high-throughput
781 microbial community data. *GigaScience*. 2013;2.
- 782 83. Martino C, Morton JT, Marotz CA, Thompson LR, Tripathi A, Knight R, et al. A Novel Sparse
783 Compositional Technique Reveals Microbial Perturbations. *mSystems*. 2019;4:e00016-19.
- 784 84. Chong J, Soufan O, Li C, Caraus I, Li S, Bourque G, et al. MetaboAnalyst 4.0: towards more transparent and
785 integrative metabolomics analysis. *Nucleic Acids Res*. 2018;46:W486–94.
- 786 85. Anderson MJ. A new method for non-parametric multivariate analysis of variance. *Austral Ecol*.
787 2001;26:32–46.
- 788 86. R Core Team. R: a language and environment for statistical computing [Internet]. R Found. Stat. Comput.
789 Vienna Austria. 2019 [cited 2019 Nov 21]. Available from: <https://www.R-project.org/>
- 790 87. Glinton KE, Elsea SH. Untargeted Metabolomics for Autism Spectrum Disorders: Current Status and Future
791 Directions. *Front Psychiatry*. 2019;10.
- 792 88. Mizejewski GJ, Lindau-Shepard B, Pass KA. Newborn screening for autism: in search of candidate
793 biomarkers. *Biomark Med*. 2013;7:247–60.
- 794 89. Lee M, Martin-Ruiz C, Graham A, Court J, Jaros E, Perry R, et al. Nicotinic receptor abnormalities in the
795 cerebellar cortex in autism. *Brain J Neurol*. 2002;125:1483–95.
- 796 90. Janecka M, Kodesh A, Levine SZ, Lusskin SI, Viktorin A, Rahman R, et al. Association of Autism Spectrum
797 Disorder With Prenatal Exposure to Medication Affecting Neurotransmitter Systems. *JAMA Psychiatry*.
798 2018;75:1217–24.
- 799 91. Saigal S, Doyle LW. An overview of mortality and sequelae of preterm birth from infancy to adulthood. *The*
800 *Lancet*. 2008;371:261–9.
- 801 92. Gil AM, Duarte D. Biofluid Metabolomics in Preterm Birth Research. *Reprod Sci*. 2018;25:967–77.
- 802 93. Ernst M, Rogers S, Lausten-Thomsen U, Bjorkbom A, Laursen SS, Courraud J, et al. Gestational-age-
803 dependent development of the neonatal metabolome. *medRxiv*. Cold Spring Harbor Laboratory Press;
804 2020;2020.03.27.20045534.
- 805 94. Dionisi-Vici C, Deodato F, Roschinger W, Rhead W, Wilcken B. “Classical” organic acidurias, propionic
806 aciduria, methylmalonic aciduria and isovaleric aciduria: Long-term outcome and effects of expanded newborn
807 screening using tandem mass spectrometry. *J Inherit Metab Dis*. Springer; 2006;29:383–9.
- 808 95. Milani C, Duranti S, Bottacini F, Casey E, Turrone F, Mahony J, et al. The First Microbial Colonizers of the
809 Human Gut: Composition, Activities, and Health Implications of the Infant Gut Microbiota. *Microbiol Mol Biol*
810 *Rev MMBR*. 2017;81.
- 811 96. Backhed F, Roswall J, Peng Y, Feng Q, Jia H, Kovatcheva-Datchary P, et al. Dynamics and Stabilization of
812 the Human Gut Microbiome during the First Year of Life. *Cell Host Microbe*. 2015;17:690–703.
- 813 97. Rosa PSL, Warner BB, Zhou Y, Weinstock GM, Sodergren E, Hall-Moore CM, et al. Patterned progression
814 of bacterial populations in the premature infant gut. *Proc Natl Acad Sci*. 2014;111:12522–7.

- 815 98. Wilmanski T, Rappaport N, Earls JC, Magis AT, Manor O, Lovejoy J, et al. Blood metabolome predicts gut
816 microbiome α -diversity in humans. *Nat Biotechnol.* 2019;37:1217–28.
- 817 99. Meng D, Sommella E, Salviati E, Campiglia P, Ganguli K, Djebali K, et al. Indole-3-lactic acid, a metabolite
818 of tryptophan, secreted by *Bifidobacterium longum* subspecies *infantis* is anti-inflammatory in the immature
819 intestine. *Pediatr Res.* Nature Publishing Group; 2020;1–9.
- 820 100. Laursen MF, Sakanaka M, Burg N von, Andersen D, Mörbe U, Rivollier A, et al. Breastmilk-promoted
821 bifidobacteria produce aromatic lactic acids in the infant gut. *bioRxiv.* Cold Spring Harbor Laboratory;
822 2020;2020.01.22.914994.
- 823 101. Keller MC, Fredrickson BL, Ybarra O, Cote S, Johnson K, Mikels J, et al. A warm heart and a clear head -
824 The contingent effects of weather on mood and cognition. *Psychol Sci.* Blackwell Publishing; 2005;16:724–31.
- 825 102. D’Amato G, Holgate ST, Pawankar R, Ledford DK, Cecchi L, Al-Ahmad M, et al. Meteorological
826 conditions, climate change, new emerging factors, and asthma and related allergic disorders. A statement of the
827 World Allergy Organization. *World Allergy Organ J.* Elsevier; 2015;8:UNSP 25.
- 828 103. Ruoppolo M, Scolamiero E, Caterino M, Mirisola V, Franconi F, Campesi I. Female and male human
829 babies have distinct blood metabolomic patterns. *Mol Biosyst.* 2015;11:2483–92.
- 830 104. Diaz SO, Pinto J, Barros AS, Morais E, Duarte D, Negrão F, et al. Newborn Urinary Metabolic Signatures
831 of Prematurity and Other Disorders: A Case Control Study. *J Proteome Res.* 2016;15:311–25.
- 832 105. Challis J, Newnham J, Petraglia F, Yeganegi M, Bocking A. Fetal sex and preterm birth. *Placenta.*
833 2013;34:95–9.
- 834 106. Wilkin TJ, Murphy MJ. The gender insulin hypothesis: why girls are born lighter than boys, and the
835 implications for insulin resistance. *Int J Obes.* 2006;30:1056–61.
- 836 107. Wehrens R, Hageman JosA, van Eeuwijk F, Kooke R, Flood PJ, Wijnker E, et al. Improved batch
837 correction in untargeted MS-based metabolomics. *Metabolomics.* 2016;12.
- 838 108. Petrick L, Edmands W, Schiffman C, Grigoryan H, Perttula K, Yano Y, et al. An untargeted metabolomics
839 method for archived newborn dried blood spots in epidemiologic studies. *Metabolomics Off J Metabolomic Soc.*
840 2017;13.
- 841 109. Folketinget. Bekendtgørelse af lov om videnskabetisk behandling af sundhedsvidenskabelige
842 forskningsprojekter - (The Danish Parliament. Order of law on scientific treatment of health scientific research
843 projects) [Internet]. *retsinformation.dk.* 2017 [cited 2019 Oct 28]. Available from:
844 <https://www.retsinformation.dk/Forms/r0710.aspx?id=192671>

845

846 **Tables**

847 **Table 1. Subjects characteristics**

	All subjects n = 74				After outlier removal n = 68				
	cases		controls		cases		controls		
Age at 1st Jan. 2006 (months, median (range))	7.6	(0.8-11.6)	7.6	(0.8-11.6)	7.3	(0.8-11.6)	7.5	(0.8-11.6)	
Gender (girls / boys)	8 / 29		8 / 29		7 / 25		8 / 28		
Classification of cases (ICD10)¹									
- F84.0 Childhood autism	17		-		15		-		
- F84.1 Atypical autism	7		-		6		-		
- F84.5 Asperger syndrome	4		-		3		-		
- F84.8 Other pervasive developmental disorders	4		-		4		-		
- F84.9 Unspecified pervasive developmental disorders	11		-		10		-		
Gestational age (weeks, median (range), NA)	40	(33-42)	5	39 (30-42)	2	40 (33-41)	4	39 (30-42)	2
Birthweight (g, median (range), NA)	3500	(2210-4880)	1	3480 (977-4850)	2	3498 (2210-4880)	0	3490 (977-4850)	2
Age at sampling (days, median (range), NA)	6	(3-9)	3	6 (4-10)	3	6 (3-9)	2	6 (4-10)	3
Age of mother at birth (years, median (range))	31.7	(20.8-41.5)	31.7	(18.3-41.2)	32.3	(20.8-41.5)	31.8	(18.3-41.2)	

848 ¹ ICD10 classification [2]

849 More details are provided in Additional file 6.

850

851

852

853 **Table 2. Differentially abundant features in univariate analyses without FDR correction (p<0.01) and/or with high fold-change**
 854 **meeting inspection criteria**

Putative annotation of relevant compounds	Annotation level ¹	m/z	RT (min)	ID	p-value t-test		p-value Wilcoxon rank-sum test		FC ²	Network connections ³
					without FDR correction	with FDR correction	without FDR correction	with FDR correction		
Methacholine C ₈ H ₁₈ NO ₂ ⁺	2 ⁴	160.13315	0.45	159	0.0021	0.9174	0.0031	0.9434	1.25	connected to 1853 (-0.036 m/z)
SIRIUS 99.96%: C ₁₁ H ₂₂ N ₂ O ₃ (M+H ⁺)	4	231.17005	2.78	5593	0.0072	0.9174	0.0138	0.9434	1.46	Single node
SIRIUS 7.12%: C ₃₆ H ₆₃ N ₂₁ O ₁₄ (M+H ⁺)	4	1014.48923	6.64	8605	0.0414	0.9174	0.0179	0.9434	0.42	Single node

855 ¹ Annotation level of confidence according to the Metabolomics Standards Initiative (i.e. putative annotation) [68,69].

856 ² FC: Fold-change (case/control)

857 ³ Network connections in GNPS feature-based molecular network.

858 ⁴ Source of annotation mzCloud (89.9% score). See its mass spectrum in Additional file 10.

859 Inspection criteria: peak integration or shape quality, initial missing values, single values plot, presence and consistence in replicated
 860 pool injections, annotation or connection to contaminants. For details see Additional file 7.

861

862

863

864

865

866

867 **Table 3. Compounds reported in the literature three or more times as being associated with ASD**

Compound name	Annotation level ¹	Raw formula	<i>m/z</i> [M+H] ⁺	RT (min)	Feature ID (MZmine 2.41)	Detected by Compound Discoverer 2.1	HMDB ID	Literature reference
Arginine	1	C6H14N4O2	175.11895	0.35	1450	ND	HMDB0000517	[38,44,50]
Aspartic acid	1	C4H7NO4	134.04478	0.41	1073	ND	HMDB0000191	[34,35,40,41,50,57]
Citric acid	4	C6H8O7	193.03428	0.35	1776	yes	HMDB0000094	[40,42,51]
Creatine	2	C4H9N3O2	132.07675	0.40	16	yes	HMDB0000064	[42,47,52]
Creatinine	2	C4H7N3O	114.06619	0.40	281	yes	HMDB0000562	[40,50,52,53]
Decanoylcarnitine	1	C17H33NO4	316.24823	6.00	3633	yes	HMDB0000651	[37,41,57]
Glutamic acid	1	C5H9NO4	148.06043	0.38	136	yes	HMDB0000148	[34,35,38,40–43,52]
Glutamine	2	C5H10N2O3	147.07642	0.40	107	yes	HMDB0000641	[35,38,39]
Glycine	3	C2H5NO2	76.03930	0.38	1177	ND	HMDB0000123	[34,39,43,47,49,52]
Glycolic acid	-	C2H4O3	77.02332	-	ND	ND	HMDB0000115	[53–55]
Hippuric acid	2	C9H9N1O3	180.06552	3.04	5174	ND	HMDB0000714	[48,51,52,54]
Histidine	2	C6H9N3O2	156.07675	0.32	342	yes	HMDB0000177	[34,49,56]
Lactic acid	-	C3H6O3	91.03897	-	ND	ND	HMDB0000190	[35,44,52]
p-cresol	-	C7H8O1	109.06479	-	ND	ND	HMDB0001858	[34,35,53,56]
Phenylalanine	1	C9H11NO2	166.08625	1.70	594+5370+287	yes	HMDB0000159	[34,56,57]
Serine	2	C3H7NO3	106.04987	0.40	437	ND	HMDB0000187	[34,40,42,43,49]
Succinic acid	-	C4H6O4	119.03388	-	ND	ND	HMDB0000254	[40,47,48,54]
Taurine	3	C2H7NO3S	126.02194	0.43	428	ND	HMDB0000251	[25,44,47–49,52]
Threonine	2	C4H9NO3	120.06552	0.40	476	ND	HMDB0000167	[38,42,49,50]
Tryptophan	2	C11H12N2O2	205.09715	2.53	164	yes	HMDB0000929	[38,41,52,55,56]
Tyrosine	1	C9H11NO3	182.08117	0.72	58	yes	HMDB0000158	[35,42,57]
Valine	2	C5H11NO2	118.08625	0.42	ND	yes	HMDB0000883	[34,39,52]

868 ND: not detected

- 869 ¹ Annotation level of confidence according to the Metabolomics Standards Initiative (i.e. putative annotation) [68,69].
- 870 When the [M+H]⁺ adduct could not be found (+/- 5 ppm), common adducts were searched including [M+Na]⁺, [M+K]⁺, [M+2H]²⁺,
- 871 [M+H-H₂O]⁺.
- 872 See full list of compounds considered and more details in Additional file 11.

873 **Figures**


874 Figure 1. Feature-based molecular network displaying the 15 predominant putative chemical classes
875 and their subclasses

876 Nodes represent mass spectral features and are used as a proxy for a metabolite. Connected nodes
877 represent high tandem mass spectral similarity, and thus high chemical structural similarity. The
878 thickness of the grey edges connecting nodes varies according to the cosine score representing to what
879 extent two connected metabolites are chemically similar (based on MS2 spectra, from 0.7: less similar
880 and thin edge to 1.0: identical and thick edge).


881 The name of annotated metabolites (levels 1 and 2), details on chemical classes with fewer than 4
882 metabolites (absent on this figure), chemical classification scores [73], all unknowns, and group
883 intensities for all features (average, standard deviations) are detailed in Additional file 7.

884 [See Figure_1.pdf](#)

885



886 Figure 2. Network of molecular features putatively annotated as bile acids with average group
887 intensities, fold change values, mass differences and cosine scores displayed.
888 Molecular family #75 is composed of eight bile acid structural analogues (see details in Additional File
889 7). Coloring according to the fold change values makes it easier to spot the families with differential
890 abundance in cases vs. controls. Displaying average intensities for the three groups (cases, controls,
891 paper blanks) allows for a quick control of the noise (paper blanks, here no noise detected) and
892 confirmation of fold change. On edges, while the thickness of the connection represents to what extent
893 two metabolites are chemically similar, the mass difference is essential to support annotation as it
894 translates into how molecules differ from one another (e.g. water loss, conjugation, adducts, etc.).
895 [See Figure_2.pdf](#)
896



bioRxiv preprint doi: <https://doi.org/10.1101/2020.04.17.20069153>; this version posted April 22, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

897 Figure 3. Bray-Curtis principal coordinates analysis of the 68 samples after outlier removal.
898 Each sphere represents one sample. Axes are principal components 1 (x) and 3 (y) explaining 18.48%
899 and 8.79% of the variability in the data, respectively. The four replicated pool injections cluster
900 satisfactorily.


901 a) Coloring reflects the type of samples, i.e. cases, controls and four replicated pool injections. No clear
902 distinction between cases and controls can be observed (PERMANOVA Adonis $R^2 = 0.014$, P-value =
903 0.777).

904 b) Coloring reflects the month of birth for the 68 samples as well as the four replicated pool injections.
905 Samples collected in the winter (dark purple and yellow, extremities of the colors scale) are positioned
906 away from the samples collected in summer (green and turquoise, middle of the color scale). 26.2% of
907 the variation in the data can be explained by month of birth (Adonis $R^2 = 0.262$, P-value = 0.001)
908 See Additional file 8 for detailed values with and without FDR correction and for other distance
909 matrices.


910 [See Figure_3ab.pdf](#)

911


Axis 3 (8.792 %)



Axis 3 (8.792 %)



912 Figure 4. PERMANOVAs of the four tested distance matrices showing how much of the variation
913 (Adonis R^2) is explained by a metadata variable.
914 P-values include FDR correction. A star is present when the corrected p-values was <0.05 .
915 All exact values are available in Additional file 8 and detailed metadata (subject characteristics) are
916 available in Table 1 and Additional file 6.
917 [See Figure_4.pdf](#)
918
919



920 **Additional files**

921 Additional file 1:

922 Standardized reporting of untargeted metabolomics LC-MS/MS method according to [60] containing
923 the list of internal standards from the Neobase Non-derivatized MSMS kit and their concentration in
924 the extraction buffer

925 [See .xlsx](#)

926

927 Additional file 2:

928 MZmine batch .xml file used to preprocess the raw data

929 [See .xml](#)

930

931 Additional file 3:

932 Compound Discoverer 2.1 preprocessing workflow settings

933 [See .pdf](#)

934

935 Additional file 4ab:

936 PEG (4a) and PPG (4b) filtering scripts using the Kendrick Mass filter according to [80]

937 [See the two .ipynb](#)

938 [Can be opened using https://jupyter.org/](https://jupyter.org/)

939

940 Additional file 5:

941 Targeted analysis of outliers using TraceFinder (IS and unlabeled homologs) and heatmap of
942 untargeted analysis

943 [See .pdf](#)

944

945 Additional file 6:

946 Subjects characteristics in details

947 [See .xlsx](#)

948

949 Additional file 7:

950 All features including annotated compounds. Out of the 4360 features detected, 150 could be annotated
951 by GNPS library matching (annotation level 2) or in-house Trace Finder library (annotation level 1)
952 and an additional 859 by MolNetEnhancer (annotation level 3).

953 [See .xlsx](#)

954

955 Additional file 8:

956 PERMANOVAs Adonis R^2 values and p-values calculated with (74 samples) and without (68 samples)
957 outliers

958 [See .xlsx](#)

959

960 Additional file 9:

961 Full list of compounds with t-test p value <0.01 without FDR correction and/or with Wilcoxon rank-
962 sum test p value <0.01 without FDR correction and/or case/control fold change value <0.5 or >2 .

963 [See .xlsx](#)

964

965 Additional file 10: Fragmentation profiles of the two unknown features to be monitored in future
966 studies as well as methacholine as shown in Table 2.

967 [See .pdf](#)

968

969 Additional file 11: Full list of compounds reported in the literature as involved in ASD and considered
970 in this study.

971 [See .xlsx](#)

972